BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Isconova and Genocea Biosciences Expand Collaboration


8/22/2011 10:46:10 AM

UPPSALA, August 22, 2011 -- Isconova AB, a leading international vaccine adjuvant company and Genocea Biosciences, Inc., a vaccine discovery and development company pioneering a new class of T cell-based vaccines, today announced the expansion of their collaboration granting Genocea the right to use Isconova’s Matrix M™ in vaccines targeting two additional diseases.

The new disease targets included in the global collaboration are malaria and gonorrhoea. Genocea currently has the right to use Matrix M™ in vaccines targeting six infectious diseases including programs in its pipeline for herpes simplex virus type-2, Chlamydia trachomatis, and Streptococcus pneumoniae.

The lead program of the collaboration is a therapeutic vaccine for herpes simplex virus type-2. HSV-2 is a sexually transmitted disease that is estimated to infect more than 500 million people worldwide. Genocea expects to initiate human trials with this program in 2012.

Chip Clark, CEO of Genocea commented;

“A safe and effective adjuvant that elicits strong B and T cell immune response is essential to our aim to prevent or treat the world’s most intractable infectious diseases. For that reason we are delighted to expand our collaboration with Isconova for Matrix M.”

Lena Söderström, CEO of Isconova, commented;

“We are pleased that the very promising vaccine discovery and development company Genocea has selected Isconovas Matrix M™ for use in two additional diseases, thus confirming the strengths of our products. All the targeted diseases of the collaboration have high unmet medical needs and therefore significant commercial potential.”

For more information, please contact:

Lena Söderström, CEO Isconova

Tel +46 70-816 39 12, e-mail: lena.soderstrom@isconova.com

Chip Clark, CEO Genocea

Tel +1 (617) 876-8191, e-mail: chip.clark@genocea.com

About Isconova

Isconova AB is a leading international vaccine adjuvant company. Isconova has vast knowledge of vaccine systems and the company develops vaccines together with partners in the human and veterinary markets. The first vaccine using Isconovas nano-particle Matrix technology, Equilis®Prequenza, was launched on the veterinary market in 2005. In the human market a number of vaccines are under development with Isconova’s third generation nano-particle, Matrix MTM. Isconova’s partners include Crucell, Pfizer, Merck & Co., The Jenner Institute, Genocea and Evolva. The Company is headquartered in Uppsala, Sweden.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->